More articles from Clinical (Endocrine/Neuroendocrine)

Open Access
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE
Jonathan R. Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, Edward M. Wolin, Beth R. Chasen, Matthew H. Kulke, David L. Bushnell, Martyn E. Caplin, Richard P Baum, Andrew E. Hendifar, Kjell Öberg, Philippe Ruszniewski, Paola Santoro, Per Broberg, Oscar R. Leeuwenkamp and Eric P. Krenning

Journal of Nuclear Medicine March 26, 2021, jnumed.120.258897; DOI: https://doi.org/10.2967/jnumed.120.258897
You have access
First-in-human study of novel SSTR antagonist ¹⁷⁷Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy
Richard P. Baum, Jingjing Zhang, Christiane Schuchardt, Dirk Mueller and Helmut Maecke

Journal of Nuclear Medicine March 5, 2021, jnumed.120.258889; DOI: https://doi.org/10.2967/jnumed.120.258889
Open Access
Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker
David L Chan, Gary A Ulaner, David A. Pattison, David Wyld, Rahul Ladwa, Julian Kirchner, Bob T Li, W. Victoria Lai, Nick Pavlakis, PAUL J ROACH and Dale L. Bailey

Journal of Nuclear Medicine February 12, 2021, jnumed.120.257659; DOI: https://doi.org/10.2967/jnumed.120.257659
You have access
Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis
Julia Whitman, Isabel E Allen, Emily K. Bergsland, Insoo A. Suh and Thomas A. Hope

Journal of Nuclear Medicine January 15, 2021, jnumed.120.257303; DOI: https://doi.org/10.2967/jnumed.120.257303
You have access
Imaging of the glucagon receptor in subjects with type 2 diabetes
Olof Eriksson, Irina Velikyan, Torsten Haack, Martin Bossart, Iina Laitinen, Philip J Larsen, Jan-Erik Berglund, Gunnar Antoni, Lars Johansson, Stefan Pierrou, Joachim Tillner and Michael Wagner

Journal of Nuclear Medicine October 23, 2020, jnumed.118.213306; DOI: https://doi.org/10.2967/jnumed.118.213306
You have access
¹⁸F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients
Tina Binderup, Ulrich Knigge, Camilla Bardram Johnbeck, Annika Loft, Anne Kiil Berthelsen, Peter Oturai, Jann Mortensen, Birgitte Federspiel, Seppo W Langer and Andreas Kjaer

Journal of Nuclear Medicine October 16, 2020, jnumed.120.244798; DOI: https://doi.org/10.2967/jnumed.120.244798

Main menu

User menu

Search

More articles from Clinical (Endocrine/Neuroendocrine)